INTRODUCTION {#s1}
============

Over recent decades, much has been learned about the role of different proteins in controlling cell proliferation, cell movement, cell determination and cell differentiation, both in cell culture and during the development of multicellular animals. To a large extent, such knowledge was gained by comparing the behaviour of wild-type and mutant individuals, starting with large-scale genetic screens ([@BIO036749C14]; [@BIO036749C48]). Later, these approaches were complemented with reverse genetic approaches, which allowed for loss- and gain-of-function studies that could be controlled with regard to developmental time and to the targeted tissue ([@BIO036749C4]; [@BIO036749C31]; [@BIO036749C44], [@BIO036749C45]; [@BIO036749C61]; [@BIO036749C63]). To further increase the possibilities in studying protein function, RNAi- and morpholino-oligonucleotide-based methods were used to induce a reduction in protein levels. While off-target effects have to be taken into account when studying protein function with these methods, these approaches, in particular RNAi, allow for time- and tissue-controlled, genome-wide loss-of-function analyses ([@BIO036749C31]). In all of these approaches, the level of the target protein is reduced either by the lack of function of the gene or by decreased levels of mRNA. However, when studying proteins with a particularly long half-life, or in cases of maternal contribution of proteins in early embryos, it might be very difficult or even impossible to deplete the protein of interest and analyse its contribution to cellular or organismal function.

To circumvent this problem, different approaches allowing the direct manipulation of protein levels were recently developed. A number of different methods were established to degrade proteins in an inducible fashion ([@BIO036749C5]; [@BIO036749C10]; [@BIO036749C17]; [@BIO036749C26]; [@BIO036749C46]), or to remove proteins from their place of action and thereby inactivating or preventing their functions in their native environment, \['anchor away' ([@BIO036749C28]) and 'knocksideways' ([@BIO036749C53])\]. In the last few years, optogenetic tools were designed to regulate protein activity or protein dimerization; these light-controllable tools are now used in cell and developmental biology to regulate or manipulate protein function in a more controllable fashion ([@BIO036749C15]; [@BIO036749C24]; [@BIO036749C55]).

Recently, another somewhat different approach has emerged which allows targeting and manipulating proteins in several ways and in a more systematic manner. Using small protein scaffolds, it became possible to screen for and isolate binders against proteins of interest, post-translational modifications of proteins or against protein tags such as fluorescent proteins ([@BIO036749C7]; [@BIO036749C8]; [@BIO036749C27]; [@BIO036749C29]; [@BIO036749C51]; [@BIO036749C58]). Such protein binders have been used extensively, e.g. as crystallization chaperones in structural biology ([@BIO036749C6]; [@BIO036749C40]), as high-affinity reagents or sensors ([@BIO036749C11]; [@BIO036749C13]; [@BIO036749C38]; [@BIO036749C56]; [@BIO036749C60]), as detection reagents in light and super resolution microscopy ([@BIO036749C49]; [@BIO036749C52]) and for targeting medically relevant intracellular proteins ([@BIO036749C9]; [@BIO036749C23]; [@BIO036749C35]), and these reports serve just as examples.

Furthermore, functionalized protein binders have emerged as versatile tools to target and manipulate proteins *in vivo* for developmental studies. In most of these studies, binders against fluorescent proteins were used to target proteins of interest fused to the corresponding fluorescent proteins. Such functionalized binders allowed the visualization, the degradation, the delocalization or the chemical modification of the specific target, and thereby provide insight into the functional roles of proteins in developmental processes (reviewed in [@BIO036749C7]; [@BIO036749C29]; [@BIO036749C51]; [@BIO036749C58]).

In cell and developmental biology, it is now a standard procedure to use several fluorescent proteins simultaneously to analyse complex processes *in vivo* and in real time. It would therefore be valuable to have specific binders against many different fluorescent proteins in order to be able to manipulate and/or follow different proteins simultaneously. At present, only a limited number of binders for GFP (green fluorescent protein) and mCherry have been isolated and characterized ([@BIO036749C12]; [@BIO036749C21]; [@BIO036749C37]; [@BIO036749C42]).

Here, we report the selection of designed ankyrin repeat proteins (DARPins) ([@BIO036749C51]) recognizing mTFP1 (monomeric teal fluorescent protein 1). We characterized these binders both biochemically and biophysically and determined the three-dimensional structure of one DARPin-mTFP1 complex. *In vivo* functionality of anti-mTFP1 DARPins was demonstrated in delocalization experiments using Rab proteins. In the future, such manipulations could enable the generation of acute loss-of-function phenotypes in different cell types based on protein manipulation rather than genetic loss-of-function analyses.

RESULTS {#s2}
=======

We have previously reported the isolation and characterization of DARPins recognizing GFP and mCherry, including 'clamp' constructs ([@BIO036749C12]; [@BIO036749C25]). To further increase the number of orthogonal reagents available to selectively target fluorescent fusion proteins, we wanted to generate DARPins against a fluorescent protein absorbing and emitting light in a different range of the light spectrum. We decided to target mTFP1 since at the time it represented the brightest monomeric protein in the blue-green spectrum ([@BIO036749C2], [@BIO036749C3]). mTFP1 was produced recombinantly in a prokaryotic expression system and used to select DARPins against this target.

Selection and *in vitro* characterization of mTFP1-binding DARPins {#s2a}
------------------------------------------------------------------

To generate suitable DARPin binders, streptavidin-binding peptide (SBP)-tagged mTFP1 was immobilized on streptavidin beads and used as a target for DARPin selections by employing multiple rounds of Ribosome Display ([@BIO036749C19]; [@BIO036749C50]). In each round, the target concentration presented on magnetic streptavidin beads was decreased while the washing stringency was simultaneously increased to enrich for binders with high affinities. After four rounds of selection, the enriched pool was cloned into an *Escherichia coli* expression vector, allowing the production of both N-terminally His8- and C-terminally FLAG-tagged DARPins. Nearly 400 colonies of transformed *E. coli* were picked and the encoded DARPins were expressed in small scale. Bacterial crude extracts were subsequently used in enzyme-linked immunosorbent assay (ELISA) screenings, detecting the binding of candidate DARPins to streptavidin-immobilized mTFP1 by employing a FLAG-tag based detection system (data not shown). The top 30 candidates from these initial ELISA screens were analysed in more detail, testing their binding to streptavidin-immobilized mTFP1 and comparing them to the interaction with streptavidin alone. Of these analysed clones, only two candidates, named 1238_E11 and 1238_G01, showed a specific binding to mTFP1 while the majority of previous hits seemed to also be interacting with free streptavidin. This very unusually low number in this experiment, compared to the usual 50-200 specific binders, is almost certainly a consequence of attempting to immobilize the target via a streptavidin-binding peptide, instead of the usual biotin (see Discussion). The sequence of the two selected DARPins is shown in [Fig. S1A](Fig. S1A).

Specificity, affinity and epitopes of top two DARPin candidates {#s2b}
---------------------------------------------------------------

To test whether the selected DARPins 1238_E11 and 1238_G01 are specific for mTFP1, titration ELISAs against mTFP1, two other fluorophores (GFP and mCherry) and the Maltose Binding Protein (MBP) as an unrelated protein target were performed. As shown in [Fig. 1](#BIO036749F1){ref-type="fig"}A, both DARPins clearly displayed a specificity for mTFP1, with apparent affinities in the low nM range ([Fig. 1](#BIO036749F1){ref-type="fig"}A, blue curves). However, it was also noted that DARPin 1238_E11 ([Fig. 1](#BIO036749F1){ref-type="fig"}A, left panel) had both a higher apparent affinity to the target and higher background binding compared to DARPins 1238_G01 ([Fig. 1](#BIO036749F1){ref-type="fig"}A, right panel). Fig. 1.**Biochemical analyses of selected anti-mTFP1 DARPins.** (A) Titration ELISA: DARPins 1238_E11 (left panel) and 1238_G01 (right panel) show specific binding to mTFP1 over control surfaces (GFP, mCherry and MBP). (B) Fluorescence anisotropy measurements of 1238_E11 (left panel) and 1238_G01 (right panel) reveal high affinities with K~D~ values of 3 nM and 88 nM, respectively. (C) Epitope blocking ELISA. Immobilized mTFP1 was incubated with a mixture of HA- and FLAG-tagged DARPins with a relative 1:5 ratio (100 nM of the FLAG-tagged DARPins and 500 nM of the HA-tagged competitor) to analyse the influence of the competitor on the original signal (shown on left side, named 'no competition'). All the data shown in this figure originate from triplicate measurements and error bars indicate standard errors of the mean.

The affinities of these two DARPins were then measured by fluorescence anisotropy as previously described ([@BIO036749C12]) ([Fig. 1](#BIO036749F1){ref-type="fig"}B). For DARPins 1238_E11 (left panel), a high affinity with an equilibrium dissociation constant (K~D~) value of 3 nM was determined, while the affinity of 1238_G01 was found to be lower with a value of ∼88 nM.

To analyse whether the two DARPins recognize different, non-overlapping epitopes on mTFP1, competition/epitope blocking ELISAs were performed. Streptavidin-immobilized mTFP1 was incubated with a mixture of FLAG- and HA-tagged DARPins, with the HA-tagged binders being present at a fivefold higher concentration over the finally detected FLAG-tagged binders. As shown in the left panel in [Fig. 1](#BIO036749F1){ref-type="fig"}C for DARPin 1238_E11, the presence of neither the non-binding DARPin E3_5 (green striped bar), nor of the HA-tagged DARPin 1238_G01 (red striped bar) had reduced the FLAG-based detected signals. However, when the identical DARPin binder was present as an HA-tagged variant (blue striped bar), the detected signal was clearly diminished. Similar results were obtained for DARPin 1238_G01 as shown in the right panel of [Fig. 1](#BIO036749F1){ref-type="fig"}C. These data suggest that the two anti-mTFP1 DARPins bind to different epitopes on their target.

Structural analysis of the mTFP1/DARPin 1238_E11 complex {#s2c}
--------------------------------------------------------

In order to understand the basis for specificity and structural changes in the binding of the selected DARPins to mTFP1, the crystal structures of the mTFP1/DARPin 1238_E11 complex were determined ([Fig. 2](#BIO036749F2){ref-type="fig"}; [Fig. S1](Fig. S1)). The complex with DARPin 1238_G01 did not crystallize, but the structure of both isolated DARPins was determined as well (1238_G01, 1.6 Å resolution, R/R~free~ of 16/18) and (1238_E11, 2.1 Å resolution, R/R~free~ of 17/21). Fig. 2.**Structure of the mTFP1/mTFP1-DARPin 1238_E11 complex.** (A) Structural representation of mTFP1 (green) and DARPin 1238_E11 (gray). The mTFP1 chromophore is shown in sphere representation. (B) Close-up view of the binding interface of mTFP1 (green) and DARPin 1238_E11 (gray). DARPin residues are labelled in bold; hydrogen bonding interactions are indicated by black dashed lines.

The mTFP1/DARPin 1238_E11 complex was obtained by mixing mTFP1 with a 1.2-fold excess of DARPin 1238_E11 and subjecting the mixture to gel filtration. Gel filtration analysis indicated a homogeneous 1:1 complex, which was used for crystallization as described in Materials and Methods. We determined the crystal structure of the mTFP1/-DARPin 1238_E11 complex in two space groups, to 1.6 Å (P6~5~22) and 1.85 Å (C2) resolution, respectively ([Fig. 2](#BIO036749F2){ref-type="fig"}A). Both complex structures are structurally identical (C~α~ r.m.s.d. of 0.3 Å): The overall fold of mTFP1 exhibits the typical β-can motif of the GFP family ([@BIO036749C64]) and undergoes only minor structural changes upon DARPin binding ([@BIO036749C2]; [@BIO036749C30]). Similarly, upon mTFP1 binding, DARPin 1238_E11 remains structurally unchanged and exhibits only minor differences in the N-Cap region ([Fig. S1C](Fig. S1C); C~α~ r.m.s.d. of 0.45 Å). DARPin 1238_E11 binds into a cavity along mTFP1 including β-strands 1, 4, 5 and 6, comprising a protein-protein binding surface of 790 Å^2^ ([@BIO036749C36]) and thus similar in size compared to other known DARPin protein complexes ([@BIO036749C22]; [@BIO036749C57]). Residues from the N-Cap and the three DARPin repeats make specific contacts with mTFP1 ([Fig. 2](#BIO036749F2){ref-type="fig"}B). Interactions involve hydrophobic DARPin residues Trp37, Val38, Phe71, Met103 and Val104, two salt bridges (Asp69-Lys104 and Lys106-Glu15) and an arginine-arginine paring ([@BIO036749C39]; [@BIO036749C65])(Arg15-Arg178) stabilized by Glu90 ([Fig. 2](#BIO036749F2){ref-type="fig"}B).

anti-mTFP1 DARPins bind mTFP1 fusion proteins in cultured cells {#s2d}
---------------------------------------------------------------

Since many developmental and cellular processes take place in intracellular compartments, we tested the expression and functionality of the anti-mTFP1 DARPins within cells. In order to visualize the two DARPins, we fused 1238_E11 and 1238_G01 to different additional fluorescent proteins (mCherry or YPet) and used transient transfection in HeLa cells as a model system to test their properties ([@BIO036749C12]; [@BIO036749C42]). The two DARPins 1238_E11 and 1238_G01 were transfected either alone or in combination with mTFP1 fusion constructs which localize to specific compartments or specific membranes of the cells. When no mTFP1 was co-expressed, the DARPin-mCherry fusions alone were uniformly expressed and localized in both the cytoplasm and nucleus of transfected cells, with a stronger accumulation in the nuclei ([Fig. 3](#BIO036749F3){ref-type="fig"}A,B). In contrast, a mitochondrial mTFP1 'bait' alone (see Materials and Methods for a description of the mito-mTFP1 construct) was visible at the mitochondria of the transfected cells ([Fig. 3](#BIO036749F3){ref-type="fig"}C), due to the fusion with the N-terminal domain of the outer mitochondrial membrane protein MitoNEET (CISD1), which is N-terminally anchored to the outer membrane and exposed to the cytoplasmic outside of the mitochondria ([@BIO036749C18]; [@BIO036749C62]) (see [Fig. S4](Fig. S4) for a schematic representation of the fusion proteins and [Table S2](Table S2) for their amino acid sequences). When these two constructs coding for mito-mTFP1 and DARPin-mCherry were co-transfected, we observed a clear mitochondrial co-localization ([Fig. 3](#BIO036749F3){ref-type="fig"}D,E), demonstrating binding and recruitment of DARPin-mCherry to the mitochondrial surface via the mitochondrial mTFP1-bait. Fig. 3.**Intracellular binding of anti-mTFP1-DARPins.** Confocal images of HeLa cells transiently transfected with (A) pCMV-DARPin 1238_E11-mCherry alone, (B) pCMV-DARPin 1238_G01-mCherry alone, (C) pMITO-mTFP1 alone, (D) the combination of pMITO-mTFP1 and pCMV-DARPin 1238_E11-mCherry and (E) pMITO-mTFP1 and pCMV-DARPin 1238_G01-mCherry. The first column represents the mTFP1 channel (green), the second column is the mCherry channel (red), the third column is the overlay of the two channels, showing the mitochondrial co-localization (resulting in yellow) of the mito-mTFP1 bait with the respective DARPin, the fourth column represents the nuclear Hoechst staining (blue) and the fifth column is the merge of all three channels. Images were taken 24 h post transfection. Transfected constructs are indicated on top of each row and the single channels are indicated inside the panels of the first row. The merge channels are also indicated at the top of the respective columns. The figures are from a representative experiment, performed at least three times. Scale bars: 15 µm.

Nonetheless, it has to be noted that not all the DARPin molecules were recruited to the mitochondria, as seen by residual mCherry signal in the cytoplasm, presumably because of the limited number of CISD1 binding partners at the mitochondrial surface. Also, varying the ratio of the transfected DNAs did not change the amount of DARPins observed at the mitochondria (data not shown). Furthermore, the different binding affinities of the two DARPins are also not reflected in this type of experiment: it appears that these affinities are sufficient to recruit both DARPins to mitochondria in a very similar way.

To ensure that the specific binding properties of the anti-mTFP1 DARPins would work in many contexts, we also tested them for co-localization with mTFP1-baits expressed in different cellular sites ([Fig. S2](Fig. S2)) Thus, we re-localized the DARPin-mCherry fusion proteins to the nuclear compartment via binding to a histone H2B (H2B)-mTFP1 fusion ([Fig. S2](Fig. S2), first row). Indeed, a strong nuclear co-localization with this bait was observed for both DARPins ([Fig. S2](Fig. S2), second and third rows).

Finally, we tested a membrane-localizing mTFP1 bait: mTFP1-CAAX (mTFP1 with the C-terminal K-Ras farnesylation motif CVLS) together with the two anti-mTFP1 DARPins. Also in this combination, we observed a clear co-localization of the mCherry signal from both DARPin-mCherry fusion proteins with the mTFP1 signal at the cell membrane ([Fig. S2](Fig. S2), fourth, fifth and sixth rows).

To confirm that the mitochondrial and nuclear co-localizations with the respective mTFP1 baits were truly mediated by direct binding of the DARPins to mTFP1 and not by an unspecific mTFP1-mCherry interaction, we repeated the co-localization experiments in HeLa cells, fusing the DARPins to YPet, another fluorescent protein ([@BIO036749C47]). The results shown in [Fig. S3](Fig. S3) confirmed the specific binding of the DARPin-YPet constructs to the mTFP1 baits both in the nuclei and at the mitochondria.

anti-mTFP1 DARPins can be functionalized for *in vivo* relocalization experiments {#s2e}
---------------------------------------------------------------------------------

Next, we tested whether the anti-mTFP1 DARPins could bind and thereby relocalize an mTFP1-fusion protein when stably tethered to a specific subcellular compartment. For this purpose, we created an mTFP1-Rab5c fusion construct, where Rab5c would be expected to be mainly localized to the cytoplasmic face of the early endosome via its lipid anchors. In an experimental setup similar to the one previously used for an anti-GFP-DARPin ([@BIO036749C12]), we added a CAAX motif to both DARPin-YPet fusion proteins in order to tether them to the cell membrane, facing towards the cytoplasm. As anticipated, these DARPin-YPet-CAAX fusions were localized mostly along the plasma membrane of the transfected cells ([Fig. 4](#BIO036749F4){ref-type="fig"}B,C). When transfected alone, the mTFP1-Rab5c fusion construct showed both a diffuse and a 'vesicle-like' distribution, especially in the perinuclear region, but it was not observed inside the nucleus ([Figs 4](#BIO036749F4){ref-type="fig"}A and [5](#BIO036749F5){ref-type="fig"}A). In contrast, upon cotransfection with either of the membrane-tethered DARPins, mTFP1-Rab5c was relocalized to the plasma membrane ([Fig. 4](#BIO036749F4){ref-type="fig"}A versus D,E). Although some mTFP1-Rab5c was still visible in the perinuclear region, most of it was relocalized at the plasma membrane under these cotransfection conditions, thus demonstrating that both anti-mTFP1 DARPins can be functionalized for *in vivo* relocalization experiments. Fig. 4.**Rab5c recruitment to plasma membrane with anti-mTFP1-DARPins.** Confocal images of HeLa cells transiently transfected with (A) pcDNA3-mTFP1-Rab5c alone, (B) pCMV-DARPin 1238_E11-YPet-CAAX alone, (C) pCMV-DARPin 1238_G01-YPet-CAAX alone, (D) the combination of pcDNA3-mTFP1-Rab5c and pCMV-DARPin 1238_E11-YPet-CAAX and (E) pcDNA3-mTFP1-Rab5c and pCMV-DARPin 1238_G01-YPet-CAAX. The first column represents the mTFP1 channel (green), the second column is the YPet channel (red), the third column is the overlay of the two channels, showing the recruitment of mTFP1-Rab5c to the plasma membranes, the fourth column represents the nuclear Hoechst staining (blue) and the fifth column is the merge of all three channels. Images were taken 24 h post transfection. Transfected constructs are indicated on top of each row and the single channels are indicated inside the panels of the first row. The merge channels are also indicated at the top of the respective columns. The figures are from a representative experiment, performed at least three times. Scale bars: 15 µm. Fig. 5.**Rab5c trapping in the nucleus with anti-mTFP1-DARPins.** Confocal images of HeLa cells transiently transfected with (A) pcDNA3-mTFP1-Rab5c alone, (B) pCMV-DARPin 1238_E11-YPet-H2B alone, (C) pCMV-DARPin 1238_G01-YPet-H2B alone, (D) the combination of pcDNA3-mTFP1-Rab5c and pCMV-DARPin 1238_E11-YPet-H2B and (E) pcDNA3-mTFP1-Rab5c and pCMV-DARPin 1238_G01-YPet-H2B. The first column represents the mTFP1 channel (green), the second column is the YPet channel (red), the third column is the overlay of the two channels, showing the recruitment of mTFP1-Rab5c to the nuclei, the fourth column represents the nuclear Hoechst staining (blue) and the fifth column is the merge of all three channels. Images were taken 24 h post transfection. Transfected constructs are indicated on top of each row and the single channels are indicated inside the panels of the first row. The merge channels are also indicated at the top of the respective columns. The figures are from a representative experiment, performed at least three times. Scale bars: 15 µm.

Reverse anchor away with protein binders {#s2f}
----------------------------------------

In the previous experiment, we demonstrated the use of DARPins to actively intervene into a cellular process by relocalizing Rab5c from its perinuclear localization to the plasma membrane. Another way to use the intracellular protein binders would be the redistribution of a protein to a place in the cell where it can no longer exert its native function ([@BIO036749C28]; [@BIO036749C53]). We used mTFP1-tagged Rab5c together with the anti-mTFP1-DARPins, with the ultimate aim of removing Rab proteins from their natural subcellular site of action in the cytoplasm. Therefore, we fused the anti-mTFP1 DARPins-YPet to histone H2B to stably anchor them in the nucleus. Upon transfection of HeLa cells, the expression of the two DARPin-YPet-H2B fusions was exclusively nuclear, with a stronger accumulation in nucleoli or other unspecified nuclear bodies as shown in [Fig. 5](#BIO036749F5){ref-type="fig"}B,C. Cotransfection of mTFP1-Rab5c and either of the DARPin-YPet-H2B fusions clearly brought most of the mTFP1-Rab5c signal into the nuclei of the cotransfected cells, indicating active removal of mTFP1-Rab5c from its site of action, the cytoplasmic/vesicular compartment (see [Fig. 5](#BIO036749F5){ref-type="fig"}A versus D,E).

DISCUSSION {#s3}
==========

Isolation and characterization of novel reagents against mTFP1 {#s3a}
--------------------------------------------------------------

Protein binders against fluorescent proteins are valuable tools in biochemical research. Here, we report the selection of DARPins recognizing mTFP1, one of the brightest and most photostable FPs in the blue-green spectrum. While the two DARPins 1238_E11 and 1238_G01 proved to be of high value for the subsequent cellular assays, we were surprised to find a rather limited number of hits in our primary screening that satisfied our precondition of a signal of 40-fold over background. This number of hits is much lower than that in other selections performed in parallel, where typically 50 to 250 hits are found (data not shown) and this is most likely caused by the limited affinity of the streptavidin-binding peptide (SBP) to streptavidin ([@BIO036749C34]). Indeed, the immobilization strategy and washing steps in the performed Ribosome Display were previously optimized for the immobilization via biotinylated target proteins, and biotin binds essentially irreversibly to the streptavidin beads, while the SBP is washed away. Furthermore, the high percentage of identified background binders (i.e. DARPins binding to streptavidin and not mTFP1) is most likely caused by the fact that, with the immobilization via SBP, the routinely performed alternations between streptavidin and neutravidin between different rounds of Ribosome Display could not be employed, as SBP only binds to streptavidin, but not neutravidin. Therefore, we cannot recommend replacing biotinylation by streptavidin-binding peptides. Nevertheless, the two binders identified proved to be specific, having high affinity and binding to different, non-overlapping epitopes on mTFP1. This last property may render these two anti-mTFP1-DARPins suitable for a sandwich pair ([@BIO036749C25]).

Structure of the mTFP1-DARPin complex {#s3b}
-------------------------------------

Using X-ray crystallography, we obtained a crystal structure for the tightest-binding mTFP1 binding DARPin 1238_E11 in complex with mTFP1. Comparison to the crystal structures of the individual proteins showed no significant structural changes for both proteins upon complex formation. DARPin 1238_E11 binds along the barrel of mTFP1, using hydrophobic and charge complementation ([Fig. 2](#BIO036749F2){ref-type="fig"}). Anti-mTFP1 DARPin 1238_E11 and DARPin 1238_G01 differ in 13 out of 21 selected library residues ([Fig. S1A](Fig. S1A)), suggesting alternative binding epitopes, in line with the ELISA experiments ([Fig. 1](#BIO036749F1){ref-type="fig"}C). Recently, the structures of the complexes of GFP with DARPin 3G61 (PDB ID: 5MAD; [Fig. S1D](Fig. S1D)) and DARPin 3G124nc (PDB ID: 5MA6; [Fig. S1E](Fig. S1E)) were determined ([@BIO036749C25]). GFP and mTFP1 show 27% identity and 1.4 Å Cα r.m.s.d.

DARPin 3G61 and DARPin 3G124nc have an affinity to GFP in a similarly low nM range as DARPin 1238_E11 to mTFP1 ([@BIO036749C12]), but use distinct, non-overlapping epitopes to bind to the barrel of the fluorescent protein ([Fig. S1D,E](Fig. S1D,E)). This comparison shows how the beta-barrel of the autofluorescent proteins can be bound from different sides by the DARPin paratopes.

*In vivo* performance of the anti-mTFP1-DARPins {#s3c}
-----------------------------------------------

Next to other beneficial properties, DARPins fold very well and thus also display a high solubility in the intracellular milieu ([@BIO036749C51]). Indeed, both of the selected anti-mTFP1-DARPins are well distributed inside the cell and do not form aggregates, even when overexpressed under the control of the CMV promoter and/or when fused to different fluorescent proteins (mCherry and YPet) ([Fig. 3](#BIO036749F3){ref-type="fig"}; [Fig. S3](Fig. S3)). Furthermore, they are able to recognize and specifically bind mTFP1 *in vivo* in different subcellular compartments ([Fig. 3](#BIO036749F3){ref-type="fig"}; [Fig. S2](Fig. S2)). Despite having different binding affinities, both DARPins, 1238_E11 and 1238_G01, bind in a very similar way inside the cell, suggesting that both affinities are sufficiently high. More importantly, both these binders can be 'functionalized' in order to recruit an overexpressed mTFP1-Rab5c fusion protein to the plasma membrane ([Fig. 4](#BIO036749F4){ref-type="fig"}) or to trap it in the nucleus ([Fig. 5](#BIO036749F5){ref-type="fig"}), with likely different biological consequences. Nuclear relocalization of Rab5c appears to be rather efficient and might lead to an efficient depletion from the cytoplasm, allowing to assess the functional consequence of the absence of this Rab in the cytoplasm \[for such analyses, both functional copies have to be fused to mTFP1 (see below)\]. Therefore, these DARPins can now be employed in many different applications both *in vitro* and *in vivo*.

Use of mTFP1 binders in cell and developmental biology {#s3d}
------------------------------------------------------

The number of different fluorescent proteins, which vary in their absorption and emission spectrum as well as in other properties (stability, photobleaching and their ability to be photoconverted or photoactivated), has steadily increased over the last decades ([@BIO036749C54]). In order to further manipulate the *in vivo* function of proteins of interests fused to such fluorescent moieties, it would help to have an equally diverse collection of small-protein binders recognizing these fluorescent proteins. The two DARPins we report here bind specifically and with high affinity to mTFP1. The use of these novel reagents will now allow performing more complex experiments, both in cultured cells and in multicellular organisms. Similar to the large number of different optogenetic tools developed over the past years ([@BIO036749C55]), the availability of a battery of binders to different fluorescent proteins would allow for a multiparametric approach for imaging and manipulation. For example, we intend to use mTFP1-recognizing DARPins to mis-localize Rab proteins in the zebrafish vasculature and follow the behaviour of other cellular processes (e.g. trafficking of luminal and/or junctional proteins) using available marker proteins fused to GFP and red fluorescent proteins (mCherry or mKate2); for the latter two fluorescent proteins, there is a considerable number of transgenic lines available encoding fusion proteins that can be used. For such functional studies (either in cell lines or in developing organisms), both endogenous copies of the gene have to be engineered in such a way that they encode functional mTFP1-fusion proteins. Using Crispr/Cas9 technology, this is possible in many systems. Alternatively, a single rescue copy can be engineered as to encode a fusion protein, and crossed into a genetic null background of the corresponding gene. The generation of such lines in zebrafish will take some time and therefore goes beyond the scope of this study.

In summary, the novel DARPins we characterize at the structural and functional level in this study contribute to the growing toolbox of protein-directed binder modules that can be used in a large variety of applications ([@BIO036749C7]; [@BIO036749C29]; [@BIO036749C51]) and thus should be of great value for the scientific community.

MATERIALS AND METHODS {#s4}
=====================

Protein expression and purification {#s4a}
-----------------------------------

DARPin protein constructs were cloned into pQIq vectors, overexpressed in *E. coli* XL1Blue cells and purified as described previously ([@BIO036749C12]). For the expression of mTFP1, the gene fragment was cloned into the expression plasmid pRSFDuet-1 (Novagen), between BamHI and EcoRI sites, to generate N-terminally hexa-His-SBP-tagged mTFP1 fusion protein ([@BIO036749C34]). The amino acid sequence of these tagged proteins is provided in [Table S2](Table S2). The protein was overexpressed in *E. coli* BL21(DE3). After lysis of the cells in 50 mM Hepes/NaOH, 250 mM NaCl, pH 7.4, 40 mM imidazole with a sonicator and centrifugation, the proteins were purified by immobilized metal-affinity chromatography on a Ni-NTA column. For structural studies, purified mTFP1 and DARPin were mixed in a 1.2:1 ratio and then subjected to size-exclusion chromatography in 20 mM Hepes/NaOH pH 7.4 on a Superdex S75 column (GE Healthcare). The protein complex-containing fractions were pooled and concentrated in Amicon Ultra units (Millipore).

ELISA and fluorescence anisotropy (FA) assay {#s4b}
--------------------------------------------

Black 384-well Maxisorp plates (Nunc) were coated with 20 µl streptavidin (66 nM in PBS) overnight and blocked the next day with 100 µl PBS-TB (PBS containing 0.1% Tween-20 and 0.2% bovine serum albumin). After washing three times with 100 µl PBS-T, wells were coated with 20 µl of either *in vivo* biotinylated GFP, mCherry or MBP (maltose binding protein) or SBP-tagged mTFP1 at a concentration of 100 nM. Subsequently, 20 µl purified FLAG-tagged anti-mTFP1 DARPins 1238_E11 and 1238_G01 were applied in concentrations ranging from 1-50 nM and incubated for 1 h. Following another incubation with a horseradish peroxidase (HRP)-conjugated anti-FLAG antibody (Sigma-Aldrich \#A8592, 1:2500) for 1 h, bound DARPins were detected through the addition of 20 µl of an Amplex UltraRed mixture (Thermo Fisher Scientific; prepared according the manufacturer\'s instructions). Turnover of the substrate was monitored at 27°C on a Synergy™ HT Microplate Reader. All values were determined in triplicates.

For the competition ELISA, mTFP1 was immobilized on plates through its SBP-tag as described above and incubated for 1 h with 20 µl of 100 nM FLAG-tagged anti-mTFP1 DARPins alone or in combination with 500 nM HA-tagged competitor DARPins (non-binding DARPin E3_5 as well as either of the two anti-mTFP1 DARPins). For detection of the bound FLAG-tagged DARPins, wells were incubated for 1 h each with a primary mouse anti-FLAG antibody (Sigma-Aldrich \#F3165, 1:5000) and secondary goat anti-mouse-AP antibody (Sigma-Aldrich \#A3562, 1:10,000), followed by the addition of 20 µl per well of a 3 mM p-nitrophenyl phosphate solution (Sigma-Aldrich, \#71768). Absorption was measured 30 min after incubation at 37°C at 405 nm. All measurements represent technical triplicates.

The FA assay was performed as described previously ([@BIO036749C12]) using black non-binding 96-well plates (Greiner). Constant amounts of mTFP1 (15 nM) were titrated with a dilution series of DARPins (four replicates) and the fluorescence anisotropy was measured on a Tecan M1000 equipped with a suitable anisotropy module. The K~D~ was determined by fitting the data with a non-linear fit using GraphPad Prism.

Crystallization, data collection and structure determination {#s4c}
------------------------------------------------------------

All crystallization experiments were carried out with 15 mg/ml protein in sitting-drop vapour diffusion experiments. mTFP1/DARPin 1238_E11 crystals in space group C2 grew after 2 days at 4°C in 10% PEG4000, 20% glycerol and 0.02 M of L-glutamate, glycine, DL-alanine, L-lysine, DL-serine. mTFP1/DARPin 1238_E11 crystals in space group P6~5~22 grew within 1 week in 0.1 M imidazole pH 7.0 and 30% 2-methyl-2,4-pentanediol at 20°C. Plate-like crystals of DARPin 1238_G01 in space group I4 appeared after 1 week in 2 M NaCl, 10% PEG10,000 at 20°C and grew to their final size within 2 weeks. Crystals of isolated DARPin 1238_E11 in space group P2~1~ grew after 2 months in 0.2 M (NH~4~)~2~SO~4~, 0.1 M MES pH 6.5, 20% PEG8000 at room temperature. Rod-like DARPin 1238_G01 crystals in space group P2~1~2~1~2~1~ grew within 2 days in 0.2 M NaF, 20% PEG3350 at 20°C. mTFP1/DARPin 1238_E11 crystals were directly frozen in liquid nitrogen. DARPin 1238_E11 and DARPin 1238_G01 crystals were cryo-preserved by addition of ethylene glycol to a final concentration of 20% (v/v) and flash-cooled in liquid nitrogen. All measurements were done at the SLS beamlines X06DA and X06SA (Swiss Light Source, Paul Scherrer Institute, Switzerland) at 100K. All data were integrated, indexed and scaled using the XDS software package ([@BIO036749C32],[@BIO036749C33]). Data collection statistics are summarized in [Table S1](Table S1). The structures were solved by molecular replacement using the crystal structure of anti-IL4 DARPin (PDB ID: 4YDY) and mTFP1 (PDB ID: 2HQK) ([@BIO036749C2]) as search models with the program Phaser ([@BIO036749C41]). Model building, structure refinement and model validation were performed with Coot ([@BIO036749C20]), PHENIX ([@BIO036749C1]), Refmac5 ([@BIO036749C43]) and Molprobity ([@BIO036749C16]), respectively. Refinement statistics are summarized in [Table S1](Table S1). The atomic coordinates have been deposited in the RCSB Protein Data Bank and are available under the accession code 6FP7, 6FP8, 6FP9, 6FPA and 6FPB, respectively.

Plasmid construction {#s4d}
--------------------

All the eukaryotic expression plasmids were generated by specific PCR amplification and standard restriction cloning. Briefly, anti-mTFP1 DARPins, including the N-terminal His-tag and the C-terminal Flag-tag, were PCR amplified from the bacterial expression constructs and inserted into pmCherry (Hybrigenics, France). For the DARPins-YPet fusions, the mCherry coding sequence was replaced by the YPet coding sequence by standard PCR and restriction cloning. The additional polyisoprenylation CAAX peptide (GGGRSKLNPPDESGPGCMSCKCVLS) of the human K-Ras oncogene protein, or the whole human HISTH2BJ (histone H2B) coding sequence were inserted at the C-terminus of the DARPins-YPet fusion constructs for generating the membrane- (DARPins-YPet-CAAX) or nuclear (DARPins-YPet-H2B) tethering DARPins. The mitochondrial bait mito-mTFP1, containing an N-terminal anchor sequence from the human CISD1 protein (the first 59 amino acids) fused to the N-terminus of mTFP1, was generated from pcDNA4TO-mito-mCherry-10xGCN4_v4 \[Addgene plasmid 60914 ([@BIO036749C59])\] by substituting the mCherry coding sequence with that of mTFP1 and substituting the 10xGCN4_v4 tags with 1xGCN4_v4 tag. mTFP1-CAAX and HIST2BJ-mTFP1 were cloned into CMV expression vectors (pmKate2-N, Evrogen) replacing mKate2 with mTFP1 coding sequences. For the mTFP1-Rab5c fusion construct, both coding sequences of mTFP1 and zebrafish (*Danio rerio*) Rab5c were cloned in this order into pcDNA3 (Invitrogen) by standard PCR and restriction cloning. All constructs were verified by sequencing. Plasmid maps and oligonucleotide sequences for PCR and cloning are available upon request. A schematic representation of the fusion constructs is provided in [Fig. S4](Fig. S4) and their resulting fusion protein amino acid sequences are given in [Table S](Table S)[2](2).

Cell cultures, transfections and imaging {#s4e}
----------------------------------------

HeLa S3α cells (routinely checked for mycoplasm contamination) were maintained in Dulbecco\'s modified Eagle\'s medium supplemented with 10% foetal calf serum, 100 IU penicillin and 100 µg streptomycin per ml. One day before transfection, cells were seeded on glass cover slip placed into a 24-well plate at a density of 50,000-100,000 cells/well.

Transfections were carried out with 1 µg of total DNA (500 ng for each construct or with empty expression plasmid) and 3 µl of FuGENE^®^ HD Transfection Reagent (Promega), according to the manufacturer\'s instructions. 24 h post transfection, cells were fixed in 4% paraformaldehyde, stained with Hoechst 33342 (Invitrogen) and mounted on standard microscope slides with VECTASHIELD^®^ (Vector Laboratories Inc., Burlingame, USA).

Confocal images were acquired with a Leica point scanning confocal 'SP5-II-MATRIX' microscope (Imaging Core Facility, Biozentrum, University of Basel) with a 63× HCX PLAN APO lambda blue objective and 1-2×zoom.
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